



European Monitoring Centre
for Drugs and Drug Addiction

Reitox Development Framework

Roadmap 2025

May 2021

| Background

During the year 2021 new roadmaps were defined for the agency's Strategy 2025 and for its accompanying document, the Reitox Development Framework (RDF). These two roadmaps describe the activities and milestones to be implemented to reach the strategic and specific objectives set out in the longer-term strategic documents.

Given that the RDF Roadmap represents the commitment of the Reitox national focal points (NFPs) to their contribution to the EMCDDA Strategy Roadmap 2025, the EMCDDA Director proposed to present it to the Management Board for endorsement. The Executive Committee confirmed, at its meeting of 30 April 2021, the inclusion of the RDF Roadmap 2025 in the agenda of the Management Board meeting. The document was adopted by the HNFP in May 2021 and endorsed by the Management Board at their meeting on 24 June 2021.

| The RDF Roadmap 2025

This new document provides an outline of the work of the Reitox network for 2021-2025.

The table hereafter presents a series of milestones to implement the nine specific objectives of the RDF that are entirely aligned with the EMCDDA Strategy 2025.

RDF Roadmap 2025

Objectives (1)	Milestones 2025
1.1. Improve the completeness and quality of routine data collected through the Reitox network	<ul style="list-style-type: none"> ▪ Report on the mapping of all sources of information at national level and ensure that there is a (direct/effective) link with them in the Final activity report (Lead: NFPs) ▪ Maintain, consolidate and improve the reliability, timeliness, completeness and comparability of routine data collection, through gap analysis and identifying means to fill the gaps and organise capacity development activities (Lead: Centre and NFPs)
1.2. Increase the capacity of the NFPs to track and report on new developments, emerging trends and real-time data	<ul style="list-style-type: none"> ▪ Streamline sharing data with the whole network on new developments that might have a harmful impact on health or security (Lead: Centre and NFPs) ▪ Reinforce the sharing of mutual information and cooperation between the Centre and the network about the use of new data sources and new projects at European and national levels (Lead: Centre and NFPs) ▪ Improve, identify and maintain links with new sources of data to identify emerging phenomenon (Lead: NFPs) ▪ Strengthen substantially the event-based and aggregated reporting related to detection of NPS, serious adverse events as well as the related public health, safety and security components of the EU EWS in order to increase the responsiveness of the system and the preparedness at national and European level (Lead: Centre and NFPs)
1.3. Increase the capacity of the NFPs to collect and analyse data on public safety and security	<ul style="list-style-type: none"> ▪ Strengthen the capacities of the national drug information systems and of the NFPs to collect and report routine and ad hoc data in full compliance with the existing drugs market and drug-related crime indicators. Contribute on a voluntary basis, where relevant, to the conceptualisation, piloting and implementation of new data collection methods and ad hoc indicators, involving actively the competent national partners (Lead: Centre and NFPs) ▪ Strengthen the analytical capacities of the NFPs and their partners to work with market, supply and crime-related data sources at national level in order to provide comprehensive and timely description and understanding of the drugs markets and related crime; to perform national threat assessments, and contribute to the European work in this area; and preparedness in this area (Lead: Centre and NFPs) ▪ Further improve the involvement of NFPs, and related national experts, in the work of the Centre in order to contribute to joint analysis and co-production in the risks to safety and security area (Lead: Centre and NFPs)
2.1. Strengthen the capacity of the NFPs to promote and support evidence-based decisions	<ul style="list-style-type: none"> ▪ Identify the needs of the different audience groups and ways to meet them (Lead: NFPs) ▪ Improve the capacity of the NFPs to contribute to the policy debate at national level (Lead: NFPs) ▪ Finalise and disseminate the report on the potential capacity of the network to carry out monitoring on similar issues (addictions in general) (Lead: Centre and NFPs)
2.2: Reinforce the partnership between the Centre and NFPs to improve the information service to national decision-makers and practitioners	<ul style="list-style-type: none"> ▪ Streamline the Centre's and Reitox's communication activities and better coordinate them (organise meetings or other contact between communications officers) (Lead: Centre and NFPs) ▪ Pursue the involvement of the NFPs in the identification of future reporting needs taking into account lessons learned from the pandemic (Lead: Centre)

Objectives ⁽¹⁾	Milestones 2025
3.1. Assure minimum quality standards for the NFPs	<ul style="list-style-type: none"> ■ Consolidate the Certification system, with elements of self-assessment and peer support/review and promote its results (Lead: Centre and NFPs) ■ Implement quality assurance procedures at national level taking into account the EMCDDA's statistical code of practice as a useful point of reference for quantitative data collection, analysis and reporting (Lead: NFPs)
4.1. Improve the coordination of the Reitox network	<ul style="list-style-type: none"> ■ Consolidating the communication and management of the network, including with regard to preparation of meetings, support to Spokespersons, and the interaction between the Centre, the network and the NFPs in general (Lead: Centre and Reitox Spokespersons) ■ Ensure that appropriate risk management is undertaken. NFPs need to anticipate potential risks associated with their activities and identify measures to mitigate them. The Centre, in cooperation with Reitox, can provide assistance to NFPs facing difficulties accomplishing their tasks (Lead: Centre and NFPs) ■ Further involve the Reitox network in the definition of the EMCDDA's new business model and adapt procedures in line with the changes of the new model (Lead: Centre)
4.2. Increase horizontal cooperation between the NFPs	<ul style="list-style-type: none"> ■ Exchange best practices in monitoring the drug situation (Lead: Centre and NFPs) ■ Look for more EU project funding opportunities that could help to strengthen the partnership between NFPs (Lead: NFPs) ■ Increase the value of common capacity-development activities, such as Reitox Academies, and ensure that training opportunities at national level are also considered (Lead: Centre and NFPs)
4.3. Increase the external visibility of the Reitox network as a whole	<ul style="list-style-type: none"> ■ Increase the interaction/service provision between each NFP and its national drug coordinators, where appropriate, and the representative at the EMCDDA Management Board (Lead: Centre and NFPs) ■ Increasing the cooperation within 'extended/broad' networks, including candidate countries to the EU and other priority third countries (Lead: Centre and NFPs) ■ Support the Centre in preparing the candidate countries and potential candidates to build NFPs and drug information systems, and thus for full inclusion in the Reitox network, in line with the relevant EMCDDA documents (Lead: Centre and NFPs) ■ Increase the visibility of the network (e.g. at conferences, during presentations and in printed materials, Reitox network activity report, etc.) (Lead: Centre and NFPs)

⁽¹⁾ These are the nine specific objectives of the RDF, which in turn aim to implement the four strategic objectives of the document: 1) maintain the Reitox monitoring system fit for purpose; 2) strengthen the role of the NFPs in supporting decision-making and action at national level; 3) improve the overall quality of the processes and deliverables of the NFPs; 4) improve the coordination of, and cooperation within, the Reitox network.